GSTM1 and squamous cell carcinoma: Two of the three patients who received transfusion during the treatment period in Part B did not complete the study; one due to a lack of efficacy (the patient's bilirubin was normalised during most of Part B of the study, indicating pharmacological action; however, the patient's Hb value did not normalise and remained ≤10.6 g/dL during the treatment period) and the other due to an adverse event (AE) of squamous cell carcinoma that resulted in death.